MarketCap
Facebook
X
Telegram
Paratek Pharmaceuticals Income Statement 2022-2008 | PRTK
Brief overview of revenue and earnings at Paratek Pharmaceuticals
The overview follows changes across a five-year period. According to figures from Paratek Pharmaceuticals, revenue changed from 5.1 million dollars to 160 million dollars over five years. The total change was +3059.9%, with a CAGR of approximately 99.5%. The annual growth rate indicates an exceptionally strong top-line trend.
The operating result measured by EBITDA moved from −19.6 million dollars to −45.7 million dollars, or −133.3%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −386.4% to −28.5%. Higher profitability strengthens the quality of operating growth.
The final result was −21.9 million dollars initially and −63.6 million dollars in the final year. The period ended with a larger loss than it began with.
The five-year change in capitalization reached −80.2%: from 409 million dollars to 81 million dollars. The market has not yet confirmed the improvement in fundamentals.
Summary assessment
The results contain several connected negative signals. The constructive conclusion rests on a larger revenue base and higher operating efficiency. The weaker side of the profile includes a weaker market valuation, lower net income and limited operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
81 M | 196 M | 287 M | 110 M | 213 M | 409 M | 306 M | 241 M | 62.5 M | 598 K | 318 M | 320 M | - | - | - |
Shares |
54.4 M | 48.4 M | 44.2 M | 32.8 M | 31.5 M | 26.8 M | 20.3 M | 16.5 M | 2.53 M | 61.7 K | 18.6 M | 13.7 M | 13.4 M | - | - |
Historical Prices |
1.49 | 4.05 | 6.49 | 3.36 | 6.75 | 15.2 | 15.1 | 14.6 | 24.7 | 9.69 | 17 | 23.4 | |||
Net Income |
-63.6 M | -59.1 M | -25 M | -27.4 M | -22.8 M | -21.9 M | -26.5 M | -70.9 M | -17.8 M | -4.65 M | -6.55 M | -3.88 M | -9.3 M | -21.8 M | - |
Revenue |
160 M | 6 M | 16 M | 8.97 M | 17 M | 5.07 M | 29 K | - | 4.34 M | 176 K | -1.34 M | 19.7 M | 12.5 M | 5.21 M | - |
Cost of Revenue |
23.1 M | 21.5 M | 8.65 M | 3.48 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 38.3 M | 13.1 M | - | - | - | - | - | - | - | 19.7 M | - | - | - |
Operating Income |
-46.2 M | -41.1 M | -17.5 M | -23.2 M | -20 M | -20.9 M | -25.9 M | -70.1 M | -7.8 M | -7.54 M | -6.52 M | -3.76 M | -9.22 M | -22.1 M | - |
Interest Expense |
18.1 M | 17.4 M | 20.2 M | 16.4 M | 11 M | 5.08 M | 3.22 M | 770 K | 718 K | -17 K | -35 K | 9 K | 12 K | 179 K | - |
EBITDA |
-45.7 M | -40.7 M | -17 M | -24.5 M | -21.1 M | -19.6 M | -23.6 M | -69.3 M | -7.6 M | -7.44 M | -6.29 M | -3.41 M | -8.72 M | -21.5 M | - |
Operating Expenses |
- | - | 114 M | 129 M | 121 M | 97 M | 110 M | 70.8 M | 10.9 M | 26.2 M | 22.9 M | 23.5 M | - | - | - |
General and Administrative Expenses |
146 M | 119 M | 89.9 M | 89.1 M | 63.7 M | 37 M | 26.4 M | 20 M | 5.85 M | 3.39 M | 2.26 M | 12.2 M | 11 M | 16 M | - |
All numbers in USD currency
Quarterly Income Statement Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
57.3 M | 56.9 M | 56.7 M | 55.2 M | 53 M | 52.1 M | 51.7 M | 49.2 M | 47.1 M | 46.7 M | 46.5 M | 45.5 M | 43.6 M | 41.6 M | 39.8 M | 32.6 M | 32.4 M | 32.3 M | 32.3 M | 31.7 M | 31.6 M | 30.6 M | 27.9 M | 27.8 M | 27.3 M | 24.2 M | 23.4 M | 22.6 M | 17.9 M | 17.6 M | 17.6 M | 17.6 M | 16.4 M | 14.4 M | 14.4 M | 19.2 M | 19 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.7 M | 18.6 M | 18.6 M | 17.1 M | 13.9 M | 13.7 M | 13.5 M | 13.5 M | 13.5 M |
Net Income |
-14.6 M | -20.1 M | - | -20.9 M | -17.6 M | -17.9 M | -32.3 M | -18.2 M | 9.72 M | -18.3 M | -25 M | -20.9 M | -23.1 M | -27.6 M | -27.4 M | -32.6 M | -33.2 M | -35.6 M | -22.8 M | -32.1 M | -29.7 M | -27.8 M | -21.9 M | -21.3 M | -18.2 M | -27.7 M | -26.5 M | -23.6 M | -30.3 M | -31.3 M | -21.1 M | -23.4 M | -15.7 M | -10.6 M | -11.1 M | -8.2 M | -3.33 M | -2.8 M | -5.54 M | -4.7 M | -6.71 M | -10.5 M | -6.55 M | 4.86 M | -5.14 M | -5.18 M | 5.3 M | -4.99 M | -2.25 M | -1.94 M |
Revenue |
40 M | 31.2 M | - | 30.2 M | 29.6 M | 24.9 M | 31.8 M | 24.4 M | 57.5 M | 16.4 M | 16 M | 13.7 M | 9.33 M | 7.92 M | 8.97 M | 3.93 M | 2.04 M | 1.6 M | 17 M | 50 K | 40 K | 10 K | 5.07 M | 12 K | 7.51 M | 18 K | 29 K | - | - | - | - | - | - | - | 4 M | 182 K | 362 K | 418 K | 176 K | 382 K | 198 K | -5.83 M | -1.34 M | 10.4 M | 493 K | - | 12.8 M | 625 K | 3.12 M | 3.12 M |
Cost of Revenue |
4.37 M | 6.24 M | - | 4.37 M | 4.88 M | 3.49 M | - | 4.29 M | 9.78 M | 2.75 M | - | 2.02 M | 2.24 M | 1.47 M | - | 958 K | 567 K | 206 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.41 M | -15.8 M | - | -16.5 M | -13.2 M | -13.7 M | -27.3 M | -13.7 M | 14.1 M | -14.2 M | -17.5 M | -15.9 M | -18.4 M | -23.6 M | -23.2 M | -29 M | -30.1 M | -33.3 M | -20 M | -29.6 M | -27.7 M | -26.7 M | -20.9 M | -20.3 M | -16.6 M | -26.8 M | -25.9 M | -23.1 M | -29.8 M | -30.7 M | -20.4 M | -23.4 M | -15.7 M | -10.6 M | -1.91 M | -8.17 M | -3.3 M | -2.79 M | -5.52 M | -4.69 M | -6.69 M | -10.5 M | -6.52 M | 4.9 M | -5.1 M | -5.14 M | 5.33 M | -4.96 M | -2.22 M | -1.91 M |
Interest Expense |
5.29 M | 4.48 M | - | 4.54 M | 4.55 M | 4.48 M | - | 4.37 M | 4.34 M | 4.31 M | - | 5.18 M | 4.97 M | 4.83 M | -3.88 M | 4.56 M | 3.99 M | 3.23 M | -2.25 M | 3.38 M | 2.9 M | 1.51 M | -1.02 M | 1.41 M | 1.13 M | 1.13 M | -565 K | 820 K | 818 K | 730 K | -737 K | -2 K | 5 K | -171 K | -9.21 M | -35 K | -24 K | -18 K | -17 K | -17 K | -16 K | -25 K | -35 K | -45 K | -43 K | -36 K | -32 K | 2 K | 2 K | -29 K |
EBITDA |
-9.32 M | -15.8 M | - | -16.1 M | -12.9 M | -13.6 M | -27.3 M | -13.4 M | 14.3 M | -14.1 M | -17.5 M | -15.5 M | -18.2 M | -23.5 M | -23.2 M | -30.1 M | -31 M | -33.8 M | -20 M | -30.1 M | -27.4 M | -26.5 M | -20.9 M | -19.3 M | -16 M | -26.5 M | -25.9 M | -22.2 M | -29.2 M | -30.5 M | -20.4 M | -22.8 M | -15.3 M | -10.4 M | -1.91 M | -8.15 M | -3.29 M | -2.78 M | -5.52 M | -4.6 M | -6.62 M | -10.4 M | -6.52 M | 5.08 M | -4.97 M | -5.08 M | 5.33 M | -4.67 M | -2 M | -1.8 M |
General and Administrative Expenses |
36.3 M | 33.5 M | - | 33.8 M | 30.3 M | 27.6 M | - | 26 M | 27.1 M | 22.4 M | - | 20.9 M | 21 M | 23.6 M | - | 23.6 M | 20.9 M | 23.3 M | - | 13.6 M | 12.9 M | 11.9 M | - | 8.22 M | 8.72 M | 8.36 M | - | 5.95 M | 7.6 M | 6.34 M | - | 5.8 M | 4.28 M | 4.27 M | - | 3.75 M | 3.08 M | 2.5 M | 3.94 M | 2.66 M | 3.03 M | 2.8 M | 2.26 M | 2.48 M | 2.73 M | 2.78 M | 4.14 M | 2.92 M | 2.58 M | 2.54 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Paratek Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
